The direct-to-consumer genetic testing company 23andme has recently been described by journalist Erika Check Hayden as a “unicorn.”1 For Hayden, this Silicon Valley idiom describes the company’s one billion dollar valuation while also capturing the rare opportunity it affords to scientists: its two million customers make up the largest available pool of gene-linked health data.2… Read more →